new practice accelerator logo small

Sponsored by

Organogenesis_Logo_Dermagraft small

UPCOMING WEBINAR | Tuesday, April 28th at 1PM EDT (10AM PDT)

Management of Chronic Diabetic Foot Ulcers

Presenter: Dr. Windy Cole

Chronic DFUs are some of the most difficult wounds a clinician can face. It is therefore important to understand the care and interventions that patients with these wounds often need. Clinicians who encounter DFUs in their practice will find this presentation instructive because it demonstrates ways to encourage healing and prevent chronicity in DFUs.

DOWNLOADABLE WHITE PAPER

Diabetic Foot Ulcers: A Guide to Accepted Standard of Care for DFU

Diabetic foot ulcer (DFU) is a common complication of diabetes, with a high lifetime global incidence. This comprehensive guide discusses the current best practice, evidence-based standard of care for DFUs, including risk factor identification, classification, treatment goals, glycemic control, wound care, and patient education.

DOWNLOADABLE FACT SHEET

Quick Facts – Diabetic Foot Ulcers

Download Quick Facts – Diabetic Foot Ulcers and share it within your facility. This two-page fact sheet was created to support staff education on diabetic foot ulcer pathophysiology and treatment. The print-friendly format is perfect for posting on the bulletin board or distributing to your nursing staff at in-service.

OGDG_20003_728x90px_Dermagraft_MECH_01

How Much Do You Know About Diabetic Foot Ulcers?

Take our 10-question quiz to find out!

Terms to Know: Diabetic Foot Ulcers

ADA Diabetic Foot Risk Classification Table: A tool to help identify patient risk factors and urgency that includes priorities, indications, timelines, and suggested follow-ups.

Becaplermin: An FDA-approved recombinant human platelet-derived growth factor used in full-thickness lower extremity diabetic ulcers with adequate blood flow. It is a topical agent that supports the wound healing process by providing an up to 43% greater incidence of healing neuropathic ulcers (over placebo gel).

Cellular and/or tissue-based products: These treatments can be cellular and acellular based and use FDA-approved biological materials (such as placental, amniotic, or chorionic-derived substances) to provide skin cells with fibroblasts and keratinocytes to promote tissue regeneration.

READ THIS MONTH’S FEATURED ARTICLES

Diabetic Foot Ulcer Care and Patient Support

Diabetic foot ulcer (DFU) complications are challenging and costly. Evidence-based practice and advanced wound care technologies have the potential to…

Read More

Diabetic Foot Ulcers: When Standard of Care Isn’t Enough

Diabetic foot ulcers (DFUs) continue to be a major problem, causing patient suffering, burden, infections, and high mortality. The cost of DFU treatment was estimated…

Read More

Advanced Therapies for Diabetic Foot Ulcers

Advanced wound care technologies have come a long way in treating chronic wounds. However, diabetic foot ulcers (DFUs) can be challenging, and not…

Read More

Choosing an Evidence-Based Product for Diabetic Foot Ulcer Management

When determining the course of action for treating a given wound, it is important that wound care clinicians evaluate how advanced wound care therapies have…

Read More

APRIL IS DIABETIC FOOT ULCERS MONTH

Advanced Therapies for DFUs

Diabetic foot ulcers are the most common complication associated with diabetes, and can have some dire consequences. More than 50% of DFUs will become infected, and 20% of those will become infected enough to require amputation. Wound closure and the prevention of recurrence is vital in these wounds. Watch this brief overview video to learn more about DFU management and the education resources made available during this month’s Practice Accelerator.

Back To Top